Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Robert J. Mayer, MD
Dana-Farber Cancer Institute, a teaching affiliate of the Harvard
Medical School, is launching a national continuing medical education
(CME) course to bring the latest science and guidelines to community and
sub-specialist oncologists engaged in patient care.
Dana-Farber will kickoff its first program, the Master Class for Oncologists, under the direction of Robert J. Mayer, MD,
as course chair. Mayer is director of the Center for Gastrointestinal
Oncology at Dana-Farber. He also is the Stephen B. Kay Family Professor
of Medicine and associate dean of admissions at Harvard Medical School,
and a former president of ASCO (American Society of Clinical Oncology).
"Furthering the practice of cancer care and research through education is a central part of Dana-Farber's mission," says Edward J. Benz, Jr., MD,
president of Dana-Farber. "Through the master course program's
combination of online courses and live meetings, we hope to make it more
convenient for oncologists to participate in continuing medical
Benz said that in addition to members of the Dana-Farber faculty
teaching the courses, he would like to eventually include faculty from
the other Harvard teaching hospitals.
Seventy-eight percent of oncologists rely on continuing medical
education specifically to stay current on new treatment options.
Oncologists earn an average of 93 CME hours a year, with 66 percent
citing new medications or developments as prompts to seek CME.1
The first program, Master Class for Oncologists, is an 18-month program
delivered on-line and in live programs. Components are based on the
latest advances in research and treatment, covering four "tracks":
gastrointestinal cancer, breast cancer, upper respiratory malignancies,
and hematologic malignancies based on validated gaps in clinical care
and patient care needs.
"The curriculum is tailored to community oncologists needing
education on a variety of subspecialty areas in oncology, and to
sub-specialists needing great depth within their respective
sub-specialty," says Mayer who is also the vice-chair for academic
affairs in the Department of Medical Oncology at Dana-Farber.
Research has shown that physician learning outcomes are higher when
delivered by a multi-channel curriculum. The Masters Class will combine
on-line CME, convenient and accessible at point of care, and engaging
live meetings, providing real-time interaction.
The first of eight live programs will be on October 3-4, 2008 in Los
Angeles, with one more live meeting scheduled in New York on October
24-25, 2008. Six more live programs are scheduled for 2009. These
two-day events will use a team-based teaching approach. Track directors
moderate each track, poll the room for current clinical challenges,
present the interactive session and moderate a question, and answer
panel with presenting faculty.
Live meeting participants also will have access to the clinical trial
education room, where clinicians can meet one-on-one with leading
industry's researchers to discuss the latest advancements in the field
of oncology. Additionally, CME users will have access to a range of
options available on the Web site, including podcasts.
Dana-Farber Master Class for Oncologists' logistics and accreditation
partner is Pri-Med, a global provider of educational solutions. Pri-Med
Institute is the accreditation arm and will further support the
initiative by focusing attendee recruitment on practicing oncologists
and conducting in-depth outcomes research.
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal
teaching affiliate of the Harvard Medical School and is among the
leading cancer research and care centers in the United States. It is a
founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC),
designated a comprehensive cancer center by the National Cancer
1Pri-Med Physician Insights CME Behaviors Key Findings Among Oncologists, 2007, n=200